CompletedPhase 4

Intravitreous Ranibizumab as Adjunctive Treatment for Trabeculectomy in Neovascular Glaucoma

Thailand15 participantsStarted 2009-02

Plain-language summary

To evaluate the effects of intravitreal ranibizumab (IVR) as adjunctive treatment for trabeculectomy with mitomycin C (TMC) in neovascular glaucoma (NVG).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Consecutive patients with neovascular glaucoma * Age more than 80 year old * Provide written informed consent Exclusion Criteria: * Un-cooperated patients

What they're measuring

The change of intraocular pressure (IOP)

Timeframe: Change of IOP between before trabeculectomy and at last visit

Trial details

NCT IDNCT01922154

SponsorSiriraj Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2012-12

View on ClinicalTrials.gov More Glaucoma, Neovascular trials